World's Best Scientists 2026 revealed!

D-Index & Metrics

Immunology

D-Index
49
Citations
8391
World Ranking
4352
National Ranking
183

Carlo Antozzi publication distribution in Immunology in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Immunology in 2026. The highlighted bar marks where Carlo Antozzi sits on this spectrum.

62–71 publications: 9 scientists 72–81 publications: 23 scientists 82–91 publications: 40 scientists 92–101 publications: 72 scientists 102–111 publications: 86 scientists 112–121 publications: 108 scientists 122–131 publications: 150 scientists 132–141 publications: 160 scientists 142–151 publications: 159 scientists 152–161 publications: 189 scientists 162–171 publications: 166 scientists 172–181 publications: 181 scientists 182–191 publications: 188 scientists 192–201 publications: 187 scientists 202–211 publications: 178 scientists 212–221 publications: 158 scientists 222–231 publications: 168 scientists 232–241 publications: 159 scientists 242–251 publications: 160 scientists 252–261 publications: 148 scientists 262–271 publications: 116 scientists 272–281 publications: 125 scientists 282–291 publications: 115 scientists 292–301 publications: 111 scientists 302–311 publications: 95 scientists 312–321 publications: 97 scientists 322–331 publications: 97 scientists 332–341 publications: 99 scientists 342–351 publications: 96 scientists 352–361 publications: 68 scientists 362–371 publications: 76 scientists 372–381 publications: 71 scientists 382–391 publications: 71 scientists 392–401 publications: 62 scientists 402–411 publications: 54 scientists 412–421 publications: 41 scientists 422–431 publications: 63 scientists 432–441 publications: 53 scientists 442–451 publications: 31 scientists 452–461 publications: 42 scientists 462–471 publications: 40 scientists 472–481 publications: 29 scientists 482–491 publications: 34 scientists 492–501 publications: 30 scientists 502–511 publications: 23 scientists 512–521 publications: 41 scientists 522–531 publications: 29 scientists 532–541 publications: 28 scientists 542–551 publications: 16 scientists 552–561 publications: 18 scientists 562–571 publications: 18 scientists 572–581 publications: 17 scientists 582–591 publications: 17 scientists 592–601 publications: 17 scientists 602–611 publications: 19 scientists 612–621 publications: 13 scientists 622–631 publications: 12 scientists 632–641 publications: 11 scientists 642–651 publications: 16 scientists 652–661 publications: 9 scientists 662–671 publications: 5 scientists 672–681 publications: 13 scientists 682–691 publications: 12 scientists 692–701 publications: 6 scientists 702–711 publications: 6 scientists 712–721 publications: 9 scientists 722–731 publications: 9 scientists 732–741 publications: 6 scientists 742–751 publications: 11 scientists 752–761 publications: 10 scientists 762–771 publications: 7 scientists 772–781 publications: 12 scientists 782–791 publications: 7 scientists 792–801 publications: 5 scientists 802–806 publications: 1 scientists 807+ publications: 100 scientists
62 publications 807+

This scientist: 178 publications — 26th percentile

26% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 807 publications or more.

Carlo Antozzi D-index placement in Immunology in 2026

The chart shows the D-index (discipline H-index) distribution of Immunology scientists ranked by Research.com in 2026. The highlighted bar marks where Carlo Antozzi sits on this spectrum.

40–41 D-Index: 28 scientists 42–43 D-Index: 91 scientists 44–45 D-Index: 157 scientists 46–47 D-Index: 192 scientists 48–49 D-Index: 175 scientists 50–51 D-Index: 188 scientists 52–53 D-Index: 177 scientists 54–55 D-Index: 155 scientists 56–57 D-Index: 194 scientists 58–59 D-Index: 201 scientists 60–61 D-Index: 197 scientists 62–63 D-Index: 201 scientists 64–65 D-Index: 173 scientists 66–67 D-Index: 167 scientists 68–69 D-Index: 172 scientists 70–71 D-Index: 199 scientists 72–73 D-Index: 184 scientists 74–75 D-Index: 133 scientists 76–77 D-Index: 162 scientists 78–79 D-Index: 127 scientists 80–81 D-Index: 121 scientists 82–83 D-Index: 125 scientists 84–85 D-Index: 121 scientists 86–87 D-Index: 102 scientists 88–89 D-Index: 96 scientists 90–91 D-Index: 75 scientists 92–93 D-Index: 72 scientists 94–95 D-Index: 74 scientists 96–97 D-Index: 66 scientists 98–99 D-Index: 68 scientists 100–101 D-Index: 49 scientists 102–103 D-Index: 60 scientists 104–105 D-Index: 54 scientists 106–107 D-Index: 36 scientists 108–109 D-Index: 23 scientists 110–111 D-Index: 52 scientists 112–113 D-Index: 41 scientists 114–115 D-Index: 34 scientists 116–117 D-Index: 25 scientists 118–119 D-Index: 28 scientists 120–121 D-Index: 11 scientists 122–123 D-Index: 20 scientists 124–125 D-Index: 27 scientists 126–127 D-Index: 19 scientists 128–129 D-Index: 20 scientists 130–131 D-Index: 16 scientists 132–133 D-Index: 17 scientists 134–135 D-Index: 14 scientists 136–137 D-Index: 15 scientists 138–139 D-Index: 9 scientists 140–141 D-Index: 11 scientists 142–143 D-Index: 9 scientists 144–145 D-Index: 9 scientists 146–147 D-Index: 7 scientists 148–149 D-Index: 7 scientists 150–151 D-Index: 7 scientists 152–153 D-Index: 5 scientists 154–155 D-Index: 8 scientists 156 D-Index: 6 scientists 157+ D-Index: 96 scientists
40 D-Index 157+

This scientist: 49 D-Index — 13th percentile

13% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 157 D-Index or more.

Overview

Carlo Antozzi is affiliated with the Fondazione IRCCS Istituto Nazionale dei Tumori in Italy, where their research primarily focuses on neurology and related medical disciplines. Their scholarly output spans a range of topics within medicine, emphasizing neurological disorders and immunology.

The main fields of study in which Antozzi works include:

  • Medicine

Within this broad domain, their research delves deeply into several subfields:

  • Neurology
  • Infectious Diseases
  • Oncology
  • Pathology and Forensic Medicine
  • Radiology, Nuclear Medicine and Imaging

Antozzi's core topical research concentration covers:

  • Myasthenia Gravis and Thymoma
  • Peripheral Neuropathies and Disorders
  • Parkinson's Disease and Spinal Disorders
  • Antifungal resistance and susceptibility
  • Multiple Sclerosis Research Studies
  • Cancer Treatment and Pharmacology
  • SARS-CoV-2 and COVID-19 Research

Their publication record features several notable papers, including:

  • Safety and Efficacy of Nipocalimab in Patients With Generalized Myasthenia Gravis, 2023, published in Neurology
  • Safety, efficacy, and tolerability of efgartigimod in patients with generalised myasthenia gravis (ADAPT): a multicentre, randomised, placebo-controlled, phase 3 trial, 2021, published in The Lancet Neurology

Though Antozzi is a coauthor on important works in the field, some key recent publications on related topics include studies led by other scholars such as James F. Howard and Maria Pia Sormani, covering myasthenia gravis and COVID-19 impacts in neurological contexts.

Frequent collaborators of Carlo Antozzi include:

  • Renato Mantegazza
  • Rita Frangiamore
  • Fiammetta Vanoli
  • Vera Bril
  • Silvia Bonanno

The primary venues for Antozzi's publications are:

  • Neurology
  • Neurological Sciences
  • Neuromuscular Disorders
  • Zenodo (CERN European Organization for Nuclear Research)
  • The Lancet Neurology

Best Publications

  • Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre study

    James F Howard;Kimiaki Utsugisawa;Michael Benatar;Hiroyuki Murai

  • A comprehensive analysis of the epidemiology and clinical characteristics of anti-LRP4 in myasthenia gravis

    P. Zisimopoulou;P. Evangelakou;J. Tzartos;K. Lazaridis

  • Antibodies against GluR3 peptides are not specific for Rasmussen's encephalitis but are also present in epilepsy patients with severe, early onset disease and intractable seizures.

    Renato Mantegazza;Pia Bernasconi;Fulvio Baggi;Roberto Spreafico

  • Experience with immunomodulatory treatments in Rasmussen’s encephalitis

    Tiziana Granata;L. Fusco;G. Gobbi;E. Freri

  • Epstein-Barr virus persistence and reactivation in myasthenia gravis thymus

    Paola Cavalcante;Barbara Serafini;Barbara Rosicarelli;Lorenzo Maggi

  • A multicentre follow-up study of 1152 patients with myasthenia gravis in Italy

    R. Mantegazza;E. Beghi;E. Beghi;D. Pareyson;C. Antozzi

  • Long-term selective IgG immunoadsorption improves Rasmussen's encephalitis

    Carlo Antozzi;T. Granata;N. Aurisano;G. Zardini

  • Thymoma-associated myasthenia gravis: Outcome, clinical and pathological correlations in 197 patients on a 20-year experience

    Lorenzo Maggi;Francesca Andreetta;Carlo Antozzi;Fulvio Baggi

  • Breakdown of Tolerance to a Self-Peptide of Acetylcholine Receptor α-Subunit Induces Experimental Myasthenia Gravis in Rats

    Fulvio Baggi;Andrea Annoni;Federica Ubiali;Monica Milani

  • Current and emerging therapies for the treatment of myasthenia gravis

    Renato Mantegazza;Silvia Bonanno;Giorgia Camera;Carlo Antozzi

  • The thymus in myasthenia gravis: Site of "innate autoimmunity"?

    Paola Cavalcante;Rozen Le Panse;Sonia Berrih-aknin;Lorenzo Maggi

  • Complete stable remission and autoantibody specificity in myasthenia gravis.

    Fulvio Baggi;Francesca Andreetta;Lorenzo Maggi;Paolo Confalonieri

  • MuSK autoantibodies in myasthenia gravis detected by cell based assay — A multinational study

    A.I. Tsonis;A.I. Tsonis;P. Zisimopoulou;K. Lazaridis;J. Tzartos

  • A short plasma exchange protocol is effective in severe myasthenia gravis.

    Carlo Antozzi;Marco Gemma;Bruno Regi;Emilia Berta

  • Antigen-specific modulation of experimental myasthenia gravis: Nasal tolerization with recombinant fragments of the human acetylcholine receptor α-subunit

    Dora Barchan;Miriam C. Souroujon;Sin-Hyeog Im;Carlo Antozzi

  • Detection of poliovirus-infected macrophages in thymus of patients with myasthenia gravis.

    P. Cavalcante;M. Barberis;M. Cannone;F. Baggi

  • Anti-MOG autoantibodies in Italian multiple sclerosis patients: specificity, sensitivity and clinical association.

    Renato Mantegazza;Piercarlo Cristaldini;Pia Bernasconi;Fulvio Baggi

  • The natural killer cell response and tumor debulking are associated with prolonged survival in recurrent glioblastoma patients receiving dendritic cells loaded with autologous tumor lysates

    Serena Pellegatta;Marica Eoli;Simona Frigerio;Carlo Antozzi

  • COVID-19 Severity in Multiple Sclerosis: Putting Data Into Context

    Maria Pia Sormani;Irene Schiavetti;Luca Carmisciano;Cinzia Cordioli

  • Oral administration of an immunodominant T-cell epitope downregulates Th1/Th2 cytokines and prevents experimental myasthenia gravis

    Fulvio Baggi;Francesca Andreetta;Elisabetta Caspani;Monica Milani

  • Titin antibodies in “seronegative” myasthenia gravis — A new role for an old antigen

    C. Stergiou;K. Lazaridis;V. Zouvelou;J. Tzartos

  • Removal of antiacetylcholine receptor antibodies by protein-A immunoadsorption in myasthenia gravis.

    E. Berta;P. Confalonieri;O. Simoncini;G. Bernardi

  • Survival gain in glioblastoma patients treated with dendritic cell immunotherapy is associated with increased NK but not CD8+ T cell activation in the presence of adjuvant temozolomide.

    Serena Pellegatta;Marica Eoli;Valeria Cuccarini;Elena Anghileri

Frequent Co-Authors

Renato Mantegazza
Renato Mantegazza Istituto Neurologico Carlo Besta
Angela Vincent
Angela Vincent University of Oxford
Carolina Frassoni
Carolina Frassoni Istituto Neurologico Carlo Besta
Silvana Franceschetti
Silvana Franceschetti Istituto Neurologico Carlo Besta
Jorge R. Oksenberg
Jorge R. Oksenberg University of California, San Francisco
Lucia Mori
Lucia Mori University of Basel
Raffaele A. Calogero
Raffaele A. Calogero University of Turin
Lawrence Steinman
Lawrence Steinman Stanford University

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

For those interested in Immunology, related healthcare degrees offer diverse career opportunities. Nursing professionals, for example, can explore specializations that complement immunological knowledge, such as acute care. Transitioning from a family nurse practitioner (FNP) role to acute care requires additional certification, and understanding the fnp to acute care certification pathway is essential.

Accelerated programs have made it easier for aspiring practitioners to enter the field quickly. The accelerated nurse practitioner program options provide focused education for those ready to advance their clinical skills efficiently.

For individuals without a nursing background looking to enter healthcare, 12-month accelerated nursing programs online for non nurses offer a streamlined path into nursing careers closely tied to immunology-related roles.

Salary considerations also play a key role in career planning. Understanding the dnp salary by specialty can help candidates make informed decisions about their education investments and future job markets in related fields.

Best Scientists Citing Carlo Antozzi

Trending Scientists

Recently Published Articles